FATE THERAPEUTICS INC Operating Leases, Future Minimum Payments, Due in Three Years
FATE THERAPEUTICS INC (FATE) had Operating Leases, Future Minimum Payments, Due in Three Years of $3.87 million as of 2018-12-31, per its 10-K filed 2019-03-05.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears · last filed 2019-03-05
- 2018-12-31: Operating Leases, Future Minimum Payments, Due in Three Years $3.87M.
- 2017-12-31: Operating Leases, Future Minimum Payments, Due in Three Years $2.35M.
- 2016-12-31: Operating Leases, Future Minimum Payments, Due in Three Years $2.28M.
- 2013-12-31: Operating Leases, Future Minimum Payments, Due in Three Years $480.00K.
| Period end | Operating Leases, Future Minimum Payments, Due in Three Years |
|---|---|
| 2018-12-31 | $3.87M 10-K · filed 2019-03-05 |
| 2017-12-31 | $2.35M 10-K · filed 2018-03-05 |
| 2016-12-31 | $2.28M 10-K · filed 2017-03-16 |
| 2013-12-31 | $480.00K 10-K · filed 2014-03-17 |
| 2013-09-30 | $500.00K 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |